| First Author | Settleman J | Year | 2009 |
| Journal | Cancer Cell | Volume | 16 |
| Issue | 4 | Pages | 278-9 |
| PubMed ID | 19800573 | Mgi Jnum | J:153709 |
| Mgi Id | MGI:4366131 | Doi | 10.1016/j.ccr.2009.09.013 |
| Citation | Settleman J (2009) A therapeutic opportunity in melanoma: ErbB4 makes a mark on skin. Cancer Cell 16(4):278-9 |
| abstractText | Malignant melanomas are aggressive tumors that are largely refractory to conventional drug therapies. A recent study reported in Nature Genetics identified mutationally activated ErbB4 alleles in 20% of cases. These tumor cells exhibit ErbB4 dependency, suggesting that ErbB4 kinase inhibition may constitute an effective therapeutic strategy in this setting. |
